136 related articles for article (PubMed ID: 22114778)
1. Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.
Elia J; Wilson Z; La Porta LS; Algon SA; Prowler ML; Cartwright ST; McKenna PA; Laracy S; Takeda T; Borgmann-Winter K
Expert Rev Clin Pharmacol; 2011 May; 4(3):311-28. PubMed ID: 22114778
[TBL] [Abstract][Full Text] [Related]
2. Transdermal methylphenidate system: old wine in a new bottle.
Bukstein OG
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
[TBL] [Abstract][Full Text] [Related]
3. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
4. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.
Warshaw EM; Paller AS; Fowler JF; Zirwas MJ
Clin Ther; 2008 Feb; 30(2):326-37. PubMed ID: 18343271
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a methylphenidate transdermal system versus t.i.d. methylphenidate in a laboratory setting.
Pelham WE; Waxmonsky JG; Schentag J; Ballow CH; Panahon CJ; Gnagy EM; Hoffman MT; Burrows-MacLean L; Meichenbaum DL; Forehand GL; Fabiano GA; Tresco KE; Lopez-Williams A; Coles EK; González MA
J Atten Disord; 2011 Jan; 15(1):28-35. PubMed ID: 20439487
[TBL] [Abstract][Full Text] [Related]
6. Methylphenidate transdermal system.
Mays DA; Findling R
J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223. PubMed ID: 16292112
[No Abstract] [Full Text] [Related]
7. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
McGough JJ; Wigal SB; Abikoff H; Turnbow JM; Posner K; Moon E
J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
[TBL] [Abstract][Full Text] [Related]
8. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder.
Ashkenasi A
Pediatr Neurol; 2011 Dec; 45(6):381-6. PubMed ID: 22115000
[TBL] [Abstract][Full Text] [Related]
9. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
González MA; Campbell D; Rubin J
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
[TBL] [Abstract][Full Text] [Related]
10. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).
Findling RL; Dinh S
CNS Drugs; 2014 Mar; 28(3):217-28. PubMed ID: 24532028
[TBL] [Abstract][Full Text] [Related]
11. MethyPatch Noven.
Sane N; McGough JJ
Curr Opin Investig Drugs; 2002 Aug; 3(8):1222-4. PubMed ID: 12211419
[TBL] [Abstract][Full Text] [Related]
12. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art.
Arnold LE; Lindsay RL; López FA; Jacob SE; Biederman J; Findling RL; Ramadan Y
Pediatrics; 2007 Nov; 120(5):1100-6. PubMed ID: 17974748
[TBL] [Abstract][Full Text] [Related]
13. Transdermal methylphenidate (Daytrana) for ADHD.
Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
[No Abstract] [Full Text] [Related]
14. Critical assessment of the methylphenidate transdermal system.
Kowalik S; Minami H; Silva RR
Drugs Today (Barc); 2007 Aug; 43(8):515-27. PubMed ID: 17925883
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study of a methylphenidate transdermal system in children with ADHD.
Pelham WE; Manos MJ; Ezzell CE; Tresco KE; Gnagy EM; Hoffman MT; Onyango AN; Fabiano GA; Lopez-Williams A; Wymbs BT; Caserta D; Chronis AM; Burrows-Maclean L; Morse G
J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):522-9. PubMed ID: 15908834
[TBL] [Abstract][Full Text] [Related]
16. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
Anderson VR; Scott LJ
Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
[TBL] [Abstract][Full Text] [Related]
17. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
Heal DJ; Pierce DM
CNS Drugs; 2006; 20(9):713-38. PubMed ID: 16953648
[TBL] [Abstract][Full Text] [Related]
18. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
[TBL] [Abstract][Full Text] [Related]
19. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
Pierce D; Katic A; Buckwalter M; Webster K
J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
[TBL] [Abstract][Full Text] [Related]
20. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]